Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal Cancer

Dominik Paul Modest, Volker Heinemann, Sebastian Stintzing et al.|Journal of Clinical Oncology|2015

Cited by 123